Walgreens Boots Alliance exceeded analysts’ earnings expectations for the second quarter, when pharmacy sales were driven up on demand for COVID-19 tests and vaccines as the omicron variant swept the US
|WBA||WALGREENS BOOTS ALLIANCE INC.||43.86||-0.91||-2.03%|
The Deerfield, Illinois-based firm reported earnings of $1.59 per share on Thursday for the quarter ending Feb. 28, beating Wall Street’s projection of $1.40.
SECOND BOOSTER DOSE OF PFIZER, MODERNA COVID-19 VACCINES AUTHORIZED BY FDA
The company said its US retail comparable sales growth of 14.7% was the highest it has seen in more than 20 years. Revenue climbed roughly 3% to $33.76 billion, surpassing analysts’ estimate of $33.23 billion.
“Second quarter results demonstrated broad-based execution, driving strong comparable sales and robust earnings growth,” CEO Rosalind Brewer said in a statement announcing the results. “We continue to make important strides along our strategic priorities, building a consumer-centric, technology-enabled healthcare enterprise at the center of local communities,” she added.
GOP LAWMAKER CALLS FOR AN ‘OPERATION WARP SPEED’ FOR COVID-19 THERAPEUTICS
All told, the pharmaceutical giant that operates nearly 9,000 locations in the US and another 2,300-plus abroad administered 11.8 million COVID-19 vaccinations and 6.6 million COVID-19 tests in the second quarter.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Walgreens is the largest pediatric vaccine provider in the pharmacy channel, the company reported.
The Associated Press contributed to this report.